NEXICART-2 (NCT06097832) is an ongoing multi-site U.S. Phase 1/2 clinical trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory AL Amyloidosis, with a registrational design. Interim ...
Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the TD Cowen ...
Experts gathered at the TCT MedTech Innovation Forum to discuss successes, failures, barriers, and solutions in healthcare.
For technology teams, Canva’s approach offers important lessons, including a commitment to openness. “There are so many ...
Positive end of Phase I meeting and agreement reached with FDA on pivotal study design for TSC-101 Dosed first solid tumor patients with multiplex TCR-T therapy; paused further enrollment to ...
The issuer is solely responsible for the content of this announcement.
Tech Xplore on MSN
Student draws on experience to transform assistive communication
At 15, when a neurological condition took Tobias Weinberg's ability to speak, aspects of his personality became more ...
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today ...
Greenville events: holiday market, indoor golf, sports pavilion, prayer service, conservation meetup & BMW Pro-Am volunteer ...
Unprecedented Phase 1 CML efficacy data with 64% MMR achievement by 24 weeks in a refractory patient populationEncouraging safety and ...
Oral presentation Sunday, December 7, at ASH 2025 - LOS ANGELES, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), the global leader in relapsed/ ...
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback